Fed. Circ. Says Pfizer's Celebrex IP Double-Patented
The Federal Circuit on Tuesday affirmed a Virginia federal judge's March 2014 ruling invalidating a key Pfizer Inc. reissue patent covering methods for administering its blockbuster arthritis drug Celebrex, potentially paving...To view the full article, register now.
Already a subscriber? Click here to view full article